Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by a chronic inflammation of the synovial joints and infiltration of blood-derived cells. In daily practice rheumatologists use the antimetabolites methotrexate (MTX) and leflunomide for the treatment of patients with rheumatoid arthritis. The current clinical status (efficacy/toxicity) of these 2 antimetabolites in the treatment of RA will be discussed.
Original language | English |
---|---|
Pages (from-to) | 1083-8 |
Number of pages | 6 |
Journal | Nucleosides, Nucleotides and Nucleic Acids |
Volume | 23 |
Issue number | 8-9 |
DOIs | |
Publication status | Published - Oct 2004 |